SCHEMBL4892548

SCHEMBL4892548

CC(C)c1nc(NC(=O)C2COc3ccccc3O2)c(C(=O)OC(C)(C)C)n1Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 5/20 0.44
RAB9A P51151 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HTT P42858 3/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
KDM4E B2RXH2 3/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892082 0.88 MAPT (0.47) MAPTMAPK1NPC1RAB9AMEN1
SCHEMBL4892866 0.80 SMN1; SMN2 (0.46) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL3441603 0.76 L3MBTL1 (0.48) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4884454 0.72 CRHBP (0.43) MAPTMEN1KMT2AHPGDSMN1; SMN2
SCHEMBL4896089 0.72 L3MBTL1 (0.46) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL3288928 0.70 L3MBTL1 (0.46) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4886948 0.69 TSHR (0.53) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL3441807 0.69 L3MBTL1 (0.47) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL4896320 0.68 L3MBTL1 (0.54) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL3573057 0.68 L3MBTL1 (0.41) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US claimed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312305-A1 Imidazoles as Gaba- B Receptor Modulators GABRB1, GABBR2, GABRB2 MAPT 3043/4885MAPK1 3164/4885NPC1 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.